← Back to Clinical Trials
Recruiting NCT05112614

NCT05112614 Role of Gut Microbiome in Cancer Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05112614
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Hematopoietic and Lymphoid Cell Neoplasm
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2019-09-11
Primary Completion 2030-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type OBSERVATIONAL
Interventions
Biospecimen CollectionElectronic Health Record Review

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2019-09-11 with a primary completion date of 2030-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatment is delivered, and increase its effectiveness and success.

Eligibility Criteria

Inclusion Criteria: * Age 18-99 * Diagnosis of cancer and undergoing cancer therapy or scheduled to start cancer therapy or undergoing stem cell transplant for any hematological condition Exclusion Criteria: * Unable to provide informed consent * Vulnerable adults

Contact & Investigator

Central Contact

Clinical Trials Referral Office

✉ mayocliniccancerstudies@mayo.edu

📞 855-776-0015

Principal Investigator

Purna C. Kashyap, MBBS

PRINCIPAL INVESTIGATOR

Mayo Clinic in Rochester

Frequently Asked Questions

Who can join the NCT05112614 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Hematopoietic and Lymphoid Cell Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05112614 currently recruiting?

Yes, NCT05112614 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.

Where is the NCT05112614 trial being conducted?

This trial is being conducted at Scottsdale, United States, Jacksonville, United States, Rochester, United States.

Who is sponsoring the NCT05112614 clinical trial?

NCT05112614 is sponsored by Mayo Clinic. The principal investigator is Purna C. Kashyap, MBBS at Mayo Clinic in Rochester. The trial plans to enroll 3,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology